Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 GeneticVariation disease BEFREE Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder of adenine metabolism that results in excessive urinary excretion of the poorly soluble 2,8-dihydroxyadenine (DHA), leading to kidney stones and chronic kidney disease. 31378568 2020
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 Biomarker disease BEFREE Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder which leads to accumulation of poorly soluble 2,8-dihydroxyadenine in kidneys resulting in nephrolithiasis as well as chronic kidney disease from crystal nephropathy. 30355577 2018
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 Biomarker disease BEFREE Adenine phosphoribosyltransferase (APRT) deficiency is a rare, but significant, cause of kidney stones and progressive chronic kidney disease. 29241594 2018
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 Biomarker disease BEFREE Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis. 8643571 1996
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 Biomarker disease BEFREE Adenine phosphoribosyltransferase (APRT) deficiency is a hereditary purine metabolism disorder that causes kidney stones and chronic kidney disease (CKD). 30443743 2019
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 GeneticVariation disease BEFREE Adenine phosphoribosyltransferase (APRT) deficiency (OMIM #614723) is a rare autosomal recessive defect in the purine salvage pathway that causes excessive production of 2,8-dihydroxyadenine, leading to nephrolithiasis and chronic kidney disease (CKD). 30106368 2018
Entrez Id: 353
Gene Symbol: APRT
APRT
0.070 Biomarker disease BEFREE Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder characterized by 2,8-dihydroxyadenine (2,8-DHA) crystalluria that can cause nephrolithiasis and chronic kidney disease. 22212387 2012
Entrez Id: 358
Gene Symbol: AQP1
AQP1
0.010 GeneticVariation disease BEFREE We selected seven single-nucleotide polymorphisms (SNPs): rs12654812 and rs11746443 from 5q35.3 (RGS14-SLC34A1-PFN3-F12); rs12669187 and rs1000597 from 7p14.3 (INMT-FAM188B-AQP1); and rs7981733, rs1170155, and rs4142110 from 13q14.1 (DGKH (diacylglycerol kinase)), which were previously reported to be significantly associated with nephrolithiasis. rs12654812, rs12669187 and rs7981733 were significantly associated with nephrolithiasis after Bonferroni's correction (P=3.12 × 10(-3), odds ratio (OR)=1.43; P=6.40 × 10(-3), OR=1.57; and P=5.00 × 10(-3), OR=1.41, respectively). 23719187 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.020 Biomarker disease BEFREE The molecular mechanisms of androgen receptor in nephrolithiasis. 28336462 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.020 Biomarker disease BEFREE Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress. 24956378 2014
Entrez Id: 80150
Gene Symbol: ASRGL1
ASRGL1
0.010 AlteredExpression disease BEFREE SK exhibited antilithiatic and diuretic potential in ethylene glycol and sodium oxalate induced urolithiasis in ratsElevated urinary stone markers (Calcium, oxalate, uric acid, magnesium and phosphates) in plasma and renal tubular enzymes (LDH, GGT, ALP, AST ALT) in urolithiatic rats were reversed by SK treatmentSK administration significantly reduced the level of renal stress markers like Urea, Creatinine, LPO and elevated SOD, GPx, GSH levels aiding in nephroprotectionSK also provides structural and functional protection against ethylene glycol- induced renal calculus in rats as evidenced by histopathological studies. 28808392 2017
Entrez Id: 470
Gene Symbol: ATHS
ATHS
0.010 AlteredExpression disease BEFREE SK exhibited antilithiatic and diuretic potential in ethylene glycol and sodium oxalate induced urolithiasis in ratsElevated urinary stone markers (Calcium, oxalate, uric acid, magnesium and phosphates) in plasma and renal tubular enzymes (LDH, GGT, ALP, AST ALT) in urolithiatic rats were reversed by SK treatmentSK administration significantly reduced the level of renal stress markers like Urea, Creatinine, LPO and elevated SOD, GPx, GSH levels aiding in nephroprotectionSK also provides structural and functional protection against ethylene glycol- induced renal calculus in rats as evidenced by histopathological studies. 28808392 2017
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.020 Biomarker disease BEFREE Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. 30783195 2019
Entrez Id: 479
Gene Symbol: ATP12A
ATP12A
0.020 Biomarker disease BEFREE Conditional logistic regression models were adjusted for the rate of health care encounters, comorbidities, urinary tract infections, and use of thiazide and loop diuretics, proton-pump inhibitors, and statins.<b>Results</b> Exposure to any of five different antibiotic classes 3-12 months before index date was associated with nephrolithiasis. 29748329 2018
Entrez Id: 491
Gene Symbol: ATP2B2
ATP2B2
0.010 Biomarker disease BEFREE In summary, a large number of novel PMCA2-interacting proteins have been defined and a novel function of PMCA2 as a COM crystal-binding protein sheds light onto its involvement, at least in part, in kidney stone pathogenesis. 29085954 2018
Entrez Id: 495
Gene Symbol: ATP4A
ATP4A
0.020 Biomarker disease BEFREE Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. 30783195 2019
Entrez Id: 495
Gene Symbol: ATP4A
ATP4A
0.020 Biomarker disease BEFREE Conditional logistic regression models were adjusted for the rate of health care encounters, comorbidities, urinary tract infections, and use of thiazide and loop diuretics, proton-pump inhibitors, and statins.<b>Results</b> Exposure to any of five different antibiotic classes 3-12 months before index date was associated with nephrolithiasis. 29748329 2018
Entrez Id: 50617
Gene Symbol: ATP6V0A4
ATP6V0A4
0.010 GeneticVariation disease BEFREE However, heterozygous carriers of ATP6V1B1 and ATP6V0A4 mutations may have a higher risk of developing nephrolithiasis and nephrocalcinosis in adulthood, respectively. 28994037 2018
Entrez Id: 525
Gene Symbol: ATP6V1B1
ATP6V1B1
0.020 GeneticVariation disease BEFREE Haploinsufficiency of the Mouse Atp6v1b1 Gene Leads to a Mild Acid-Base Disturbance with Implications for Kidney Stone Disease. 29843146 2018
Entrez Id: 525
Gene Symbol: ATP6V1B1
ATP6V1B1
0.020 GeneticVariation disease BEFREE However, heterozygous carriers of ATP6V1B1 and ATP6V0A4 mutations may have a higher risk of developing nephrolithiasis and nephrocalcinosis in adulthood, respectively. 28994037 2018
Entrez Id: 26033
Gene Symbol: ATRNL1
ATRNL1
0.010 AlteredExpression disease BEFREE SK exhibited antilithiatic and diuretic potential in ethylene glycol and sodium oxalate induced urolithiasis in ratsElevated urinary stone markers (Calcium, oxalate, uric acid, magnesium and phosphates) in plasma and renal tubular enzymes (LDH, GGT, ALP, AST ALT) in urolithiatic rats were reversed by SK treatmentSK administration significantly reduced the level of renal stress markers like Urea, Creatinine, LPO and elevated SOD, GPx, GSH levels aiding in nephroprotectionSK also provides structural and functional protection against ethylene glycol- induced renal calculus in rats as evidenced by histopathological studies. 28808392 2017
Entrez Id: 7439
Gene Symbol: BEST1
BEST1
0.010 Biomarker disease BEFREE Parathyroidectomy results in an increase in BMD and a reduction in nephrolithiasis. 28885621 2018
Entrez Id: 632
Gene Symbol: BGLAP
BGLAP
0.010 Biomarker disease BEFREE Based on these data, it is proposed that during urolithiasis, secretion of osteopontin (uropontin) and osteocalcin (or osteocalcin-related gene/protein), and the subsequent incorporation of these proteins into kidney stone matrix, may influence the nucleation, growth processes, aggregation, and/or tubular adhesion of renal calculi in mammalian kidneys. 8619372 1995
Entrez Id: 680
Gene Symbol: BRS3
BRS3
0.010 Biomarker disease BEFREE Dent's disease, an X-linked disorder characterized by low molecular weight proteinuria, hypercalciuria, and nephrolithiasis, is due to mutations of the chloride/proton antiporter, CLC-5; ADHH is associated with activating mutations of the calcium-sensing receptor, which is a G protein-coupled receptor; hypophosphatemic hypercalciuric nephrolithiasis associated with rickets is due to mutations in the type 2c sodium-phosphate cotransporter (NPT2c); and familial hypomagnesemia with hypercalciuria is due to mutations of paracellin-1, which is a member of the claudin family of membrane proteins that form the intercellular tight junction barrier in a variety of epithelia. 17872384 2007
Entrez Id: 690
Gene Symbol: BTF3P11
BTF3P11
0.010 Biomarker disease BEFREE Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis. 29996796 2018